A rapid whole-blood adenosine triphosphate secretion test can be used to exclude platelet-dense granule deficiency
- PMID: 39938683
- DOI: 10.1016/j.jtha.2025.01.013
A rapid whole-blood adenosine triphosphate secretion test can be used to exclude platelet-dense granule deficiency
Abstract
Background: Delta storage pool disease (δ-SPD) is a rare platelet function disorder (PFD) characterized by a deficiency of dense granules or defective granule secretion, leading to bleeding diathesis. Diagnostics of δ-SPD are difficult and lack standardization, leading to underestimation of its prevalence. Current diagnostic methods are based on granule content assays or lumi-aggregometry, which have limited availability. Therefore, there is an unmet need for a rapid, accessible test for δ-SPD.
Objectives: To evaluate the diagnostic value of a rapid whole-blood adenosine triphosphate (ATP) secretion test for δ-SPD.
Methods: ATP secretion after PAR-1 activating peptide (PAR-1 AP; TRAP-6) stimulation was assessed in whole blood using luminescence in 50 healthy controls, 22 patients with a suspected PFD other than storage pool disease (non-SPD) and 25 patients with δ-SPD and corrected for platelet count. Diagnostic value of the test was determined with C-statistics, sensitivity, specificity, likelihood ratios (LLRs), and predictive values (PVs).
Results: PAR-1 AP mediated ATP secretion in the rapid test was lower in δ-SPD than in healthy controls and non-SPD patients (P < .0001). The rapid test was able to discriminate between δ-SPD and non-SPD patients (C-statistic 0.88; 95% CI, 0.78-0.98). At a cutoff value of the highest value of the δ-SPD group, the sensitivity was 100% and the specificity was 64%. This cutoff value corresponded with a positive LLR of 2.75, an optimal negative LLR of 0.00, positive PV of 76%, and negative PV of 100%.
Conclusion: A whole-blood ATP secretion test can be used to exclude ẟ-SPD in patients presenting with a primary hemostasis defect.
Keywords: blood platelet disorder; diagnostic tests; luminescent assay; platelet function tests; platelet storage pool deficiency.
Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest M.Z.: no conflicts of interest. R.E.G.S.: The institution of R.E.G. Schutgens has received speaker’s fees and/or research grants from Bayer, CSL Behring, Hemab, Novartis, Novo Nordisk, Octapharma, Roche, Sobi, and Takeda. V.v.d.V.: no conflicts of interest. J.A.L.: no conflicts of interest. M.R.: employee of Synapse Research Institute. D.H.: employee of Synapse Research Institute. A.S.d.M.: no conflicts of interest. I.C.L.K.H.: no conflicts of interest. R.T.U.: The institution of R.T. Urbanus has received research grants from Hemab.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials